Pat Mackin, Chairman, President, and Chief Executive Officer, said, "Resolving the FDA warning letter was my top priority when I joined the Company. I am pleased that we passed the recent FDA re-inspection with no 483 observations and that the FDA has lifted our warning letter. The CryoLife team did a great job responding to the FDA's concerns, and we are committed to the continued enhancement of our quality systems and delivery of the highest quality products to patients."